Amgen Inc. (AMGN) Position Lowered by LS Investment Advisors LLC
LS Investment Advisors LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 0.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 99,953 shares of the medical research company’s stock after selling 204 shares during the period. Amgen makes up 1.2% of LS Investment Advisors LLC’s holdings, making the stock its 12th largest position. LS Investment Advisors LLC’s holdings in Amgen were worth $16,673,000 as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of AMGN. Integrated Wealth Management increased its stake in Amgen by 0.3% in the second quarter. Integrated Wealth Management now owns 930 shares of the medical research company’s stock worth $141,000 after buying an additional 3 shares during the period. Goelzer Investment Management Inc. increased its stake in Amgen by 0.3% in the second quarter. Goelzer Investment Management Inc. now owns 1,604 shares of the medical research company’s stock worth $244,000 after buying an additional 5 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.5% in the third quarter. Capital Advisors Ltd. LLC now owns 1,083 shares of the medical research company’s stock worth $181,000 after buying an additional 5 shares during the period. M Holdings Securities Inc. increased its stake in shares of Amgen by 0.3% in the second quarter. M Holdings Securities Inc. now owns 1,725 shares of the medical research company’s stock worth $262,000 after buying an additional 6 shares during the period. Finally, Oakworth Capital Inc. increased its stake in shares of Amgen by 1.4% in the third quarter. Oakworth Capital Inc. now owns 711 shares of the medical research company’s stock worth $119,000 after buying an additional 10 shares during the period. 77.90% of the stock is owned by institutional investors and hedge funds.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at 156.12 on Friday. The company has a 50 day moving average of $146.78 and a 200 day moving average of $159.07. The company has a market cap of $116.14 billion, a PE ratio of 15.63 and a beta of 1.14. Amgen Inc. has a 1-year low of $133.64 and a 1-year high of $176.85.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, October 27th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.79 by $0.23. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.73 billion. Amgen had a net margin of 33.63% and a return on equity of 29.27%. Amgen’s revenue for the quarter was up 1.5% compared to the same quarter last year. During the same period in the previous year, the business earned $2.72 EPS. Equities analysts expect that Amgen Inc. will post $11.55 earnings per share for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 8th. Stockholders of record on Wednesday, February 15th will be paid a dividend of $1.15 per share. The ex-dividend date is Monday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $1.00. This represents a $4.60 annualized dividend and a dividend yield of 2.95%. Amgen’s payout ratio is currently 39.92%.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the propert of of Watch List News. If you are reading this story on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark laws. The correct version of this story can be viewed at http://www.watchlistnews.com/amgen-inc-amgn-position-lowered-by-ls-investment-advisors-llc/1061240.html.
AMGN has been the subject of a number of recent research reports. Leerink Swann set a $163.00 price objective on Amgen and gave the company a “hold” rating in a research report on Monday, November 21st. BMO Capital Markets reiterated a “buy” rating and set a $197.00 price objective on shares of Amgen in a research report on Monday, January 9th. Jefferies Group reiterated a “buy” rating on shares of Amgen in a research report on Wednesday, September 28th. Vetr upgraded Amgen from a “buy” rating to a “strong-buy” rating and set a $188.11 price objective for the company in a research report on Thursday, September 29th. Finally, Credit Suisse Group downgraded Amgen from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $200.00 to $180.00 in a research report on Tuesday, December 20th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $179.48.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.